|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Operating activities: | |||||
| Net (loss) income | |||||
| Adjustments to net (loss) income: | |||||
| Goodwill impairment | |||||
| Impairment of long-lived assets | |||||
| Provision for credit losses | |||||
| Deferred tax expense (benefit) | |||||
| Depreciation and amortization | |||||
| Amortization of developed technology and backlog | |||||
| Amortization of debt discount and issuance costs | |||||
| Gain on extinguishment of debt, net | |||||
| Gain on debt refinancing | |||||
| Equity-based compensation | |||||
| Change in fair value of contingent consideration | |||||
| Warranty provision | |||||
| Inventory Valuation Reserves | |||||
| Inventory reserve | |||||
| Other non-cash | |||||
| Changes in operating assets and liabilities, net of business acquisition: | |||||
| Accounts receivable | |||||
| Inventories | |||||
| Income tax receivables | |||||
| Prepaid expenses and other | |||||
| Accounts payable | |||||
| Accrued expenses and other | |||||
| Income tax payable | |||||
| Lease liabilities | |||||
| Deferred revenue | |||||
| Other operating assets and liabilities | |||||
| Net cash provided by operating activities | |||||
| Investing activities: | |||||
| Purchase of property, plant and equipment | |||||
| Acquisition, net of cash acquired | |||||
| Investment in equity securities | |||||
| Retirement/disposal of property, plant and equipment | |||||
| Cash payments for the acquisition of right-of-use assets | |||||
| Investment in securities | |||||
| Sale of equity investment | |||||
| Net cash used in investing activities | |||||
| Financing activities: | |||||
| Proceeds from Series A issuance | |||||
| Proceeds from common stock issuance | |||||
| Series A equity issuance costs | |||||
| Tax withholding related to vesting of equity-based compensation | |||||
| Common stock issuance costs | |||||
| Dividends paid on Series A Preferred | |||||
| Payments on revolving credit facility | |||||
| Proceeds from revolving credit facility | |||||
| Proceeds from issuance of other debt | |||||
| Proceeds from issuance of convertible notes | |||||
| Premium paid on capped call | |||||
| Fees paid on issuance of convertible notes | |||||
| Repayments of other debt | |||||
| Repayments of term loan facility | |||||
| Repayments of convertible notes | |||||
| Contingent consideration payments | |||||
| Debt issuance costs | |||||
| Other financing | |||||
| Net cash used in financing activities | |||||
| Effect of exchange rate changes on cash and cash equivalent balances | |||||
| Net change in cash and cash equivalents | |||||
| Cash and cash equivalents and restricted cash, beginning of period | |||||
| Cash and cash equivalents and restricted cash, end of period | |||||
| Cash paid for interest | |||||
| Cash paid for income taxes | |||||
| Dividends accrued on Series A Preferred | |||||
| Stock consideration paid for acquisition of STI | |||||
Loading...